Dyne Therapeutics

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boeing

U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 100 points on Tuesday.

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

- Building Team to Prepare for Commercialization as Company Pursues Expedited Approval Pathways for DM1 and DMD Clinical Programs -

Dyne Therapeutics Announces Key Leadership Appointments

- Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024 - - Virtual Investor Event Today at 8:00 a.m. ET -

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on Thursday, September 5, 2024 at 4:05 p.m. ET.

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

- Recent Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrated Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints -

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Dyne Therapeutics (DYN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why

Does Dyne Therapeutics, Inc. (DYN) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?

Dyne Therapeutics (DYN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why

WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS). The data were presented at the New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 23-26 in Fort Lauderdale, FL.

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models -

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET.

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously announced underwritten public offering of 12,075,000 shares of its common stock at a public offering price of $31.00 per share, which includes 1,575,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $374.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All of the shares in the offering were sold by Dyne.

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Dyne Therapeutics stock (NASDAQ NASDAQ : DYN), a biotechnology company focused on advancing genetically driven muscle diseases therapeutics, saw a significant 28% rise on Monday, May 20. This move came in after the company released a positive clinical trial data for its experimental drugs – DYNE-101 – for patients with myotonic dystrophy type 1, and DYNE-251 – for patients with Duchenne muscular dystrophy.

Up 165% This Year Will Dyne Therapeutics Continue Its Stellar Run?

WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $325.5 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about May 24, 2024, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

Dyne (DYN) gains 28% after reporting positive new data from two separate ongoing mid to late-stage studies evaluating DYNE-101 and DYNE-251 for different muscle disease indications.

Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies

WALTHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

Top-notch biotech stock Dyne broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy drugs.

Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again

- In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months -

Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

WALTHAM, Mass., May 19, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, and to host a virtual event at 8:00 a.m. ET. This represents an update to Dyne's prior guidance for the second half of 2024. The company intends to issue a press release prior to the start of the event.

Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET

- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 -

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an inducement equity award to its newly appointed President and Chief Executive Officer, John G. Cox. The award was approved by the Compensation Committee of Dyne and was made as an inducement material to Mr. Cox's acceptance of employment with Dyne under Dyne's 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024 at 9:50 a.m. ET.

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO -

Dyne Therapeutics Announces CEO Transition

WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET.

Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024. The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by 2033.

News for Dyne Therapeutics Stock (DYN)